Exceed Your Due Diligence and Control MSK Costs With the Regenexx Corporate Program

As a trusted advisor to self-funded employers, your responsibility is to deliver smarter healthcare strategies that dramatically lower costs and improve employee well-being. With musculoskeletal (MSK) conditions consistently dominating healthcare spend, offering a proven, evidence-based solution is no longer optional—it’s essential.

We empower you to fulfill this critical role and offer a solution that exceeds your due diligence. The Regenexx Corporate Program regularly helps partners achieve MSK spend cuts by 50% or more— directly impacting your clients’ bottom line and enhancing their benefits strategy. Read on to learn why there is no better interventional strategy to impact the cost of conservative care than a partnership with us.

Make Our Strengths Your Strategic Advantage: Seamless Onboarding, Revolutionary and Compliant MSK Care

Our team’s extensive experience, built from onboarding over 2,000 Corporate Program partners, becomes your advantage to ensure a seamless process from initial discovery through full benefit rollout. This streamlined implementation allows you to confidently introduce a game-changing solution to your self-funded clients.

The landscape of musculoskeletal (MSK) care is rapidly evolving, and Regenexx has led this charge with two decades of innovation and leadership. When you champion the Regenexx benefit, you’re not just offering another high-quality MSK option. You’re delivering a more cost-effective future for your clients and providing an MSK care solution their employees demonstrably prefer.

Our program delivers a high-value option for self-funded employers seeking a compliant, cost-saving option that passes the test for experimental and investigative procedures through key criteria including: safety, efficacy, and net clinical benefit. Partnering with the Regenexx Corporate Program allows you to offer a truly differentiated and impactful benefit.

The Regenexx Corporate Program regularly helps partners achieve MSK spend cuts by 50% or more — which often contributes to a reduction in total medical spend by up to 10%. Your clients’ MSK spend deserves a closer look from our team of experts who can help you evaluate the key areas driving cost and provide a second opinion on current strategies. Request a complimentary, comprehensive impact study that demonstrates the potential for MSK cost savings using your client’s own deidentified data.

NO COST & EASY FOR GROUPS TO ADD

The Regenexx benefit is always added at no cost to the health plan. Onboarding is as soon as 1 week pending TPA receiving SPD, onboarding form completion, benefit card text approval, and eligibility file received from TPA.

BROKER ASSISTANCE

Introductions to clients and prospects

PARTNER TO 100+ TPAs & ~100 STOP-LOSS CARRIERS

Partnerships to aid you and your clients

CLIENT MEETING MATERIALS

Resources to help inform your clients’ decisions to add the Regenexx benefit

*Timeframe to add Regenexx benefit depends on how quickly TPA receives SPD, onboarding form is completed, benefits card text is approved, and eligibility file is received from TPA.

Helping You Deliver More Value

Cost is king. It is the second largest spend next to payroll expense. If you don’t find things like regenexx – things that can take actual cost of care down, then our employer clients are forced to do other things like raise deductibles, raise contributions, all those things that, quite frankly, employees don’t want to see. And so something like this that is as simple as it is, but yet has a broad ramification, is an important step in that whole cost containment strategy.”

Lisa Hawker, Hylant TPA

As a broker, when you sell these types of services and products typically the buyer will go ‘well what do you do for your employees?’ and so whatever we do should be best in class because we’re selling it to our clients. It really has differentiated us in the marketplace by bringing new ideas and concepts to our clients… clients are constantly looking for, particularly when it comes to the medical spend, for new solutions and new alternatives to what they’ve been doing in the past just because of the cost escalation on an annual basis. When we come to the table with regenexx it’s certainly making us look better than someone else who’s not talking about it or bringing these solutions to the table.”

Michael M. Hylant, CEO of Hylant

img

Top 3 Reasons to Introduce Regenexx to your Clients

  • Surgical alternative that integrates easily with existing plans
  • Cost-containment strategy with proven data on claims reduction
  • High-impact benefit that supports workforce productivity and satisfaction

Numbers That Differentiate Your Offering

75

pending new locations in the licensed Regenexx network in 2025

20

years since Regenexx was founded by Dr. Chris Centeno and Dr. John Schultz

0

Still $0 to add the Regenexx benefit to a self-funded plan

42+

Peer-reviewed publications in high-impact journals, focusing on various applications of interventional orthobiologics

50

the number of states with locations in the licensed Regenexx network

53.6m

Regenexx Corporate Program clients saved over $53.6M in 2024

70

cost of individual elective orthopedic surgeries can be reduced by up to 70%

75

pending new locations in the licensed Regenexx network in 2025

95.23

client retention rate 95.23% since 2015

~100

stop-loss carriers who have partnered with the Regenexx Corporate Program

125

TPAs have partnered with the Regenexx Corporate Program

176

new employers added since January 2024

+2000

active, self-funded clients over all major industries

351k

covered lives added since January 2024

1.5m

Million corporate covered lives

Educate to Save: Utilization and Candidacy Drive Cost Control

The efficacy of even the most robust MSK solution hinges on employee awareness and engagement. Recognizing this, the Regenexx Corporate Program incorporates a turnkey member education strategy. This ensures employees and their families understand Regenexx as a high-quality, non-surgical option precisely when an MSK issue emerges.

Informed members who engage earlier in their care journey help drive substantial cost savings through the likelihood of surgical avoidance. Utilization review helps further ensure that patients with good candidacy ratings move forward with appropriate physician recommended care and supports cost savings by reducing unnecessary or inappropriate treatments. The utilization review process for benefit member care is founded in the clinical integrity and outcomes data of the Regenexx approach to candidacy.

This optimized utilization represents a tangible benefit brokers can confidently present and support. When members are informed, they engage earlier, avoid unnecessary surgeries, and drive real savings. It’s the kind of utilization that brokers can confidently stand behind.

img

We’re here to help.

Please complete the form below and let us know how we can support you:(Required)

Name(Required)
This field is for validation purposes and should be left unchanged.

Trusted by Leading U.S. Brokerage Firms to Reduce Healthcare Spend